ARICEPT SUMMARY
ARICEPT (donepezil hydrochloride) is a reversible inhibitor of the enzyme acetylcholinesterase, known chemically as (±)-2, 3-dihydro-5, 6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]-1 H -inden-1-one hydrochloride. Donepezil hydrochloride is commonly referred to in the pharmacological literature as E2020.
ARICEPT is indicated for the treatment of dementia of the Alzheimer's type. Efficacy has been demonstrated in patients with mild, moderate, and severe Alzheimer's disease.
|
|
NEWS HIGHLIGHTSMedia Articles Related to Aricept (Donepezil)
Alzheimer's Disease
Source: MedicineNet Immunizations Specialty [2017.06.01]
Title: Alzheimer's Disease
Category: Symptoms and Signs
Created: 8/5/2014 12:00:00 AM
Last Editorial Review: 6/1/2017 12:00:00 AM
Dementia, Alzheimer's Disease, and Aging Brains
Source: MedicineNet Hydrocephalus Specialty [2016.08.01]
Title: Dementia, Alzheimer's Disease, and Aging Brains
Category: Slideshows
Created: 12/3/2009 10:07:00 AM
Last Editorial Review: 8/1/2016 12:00:00 AM
Alzheimer's Disease Symptoms & Early Diagnosis
Source: MedicineNet memantine Specialty [2016.07.27]
Title: Alzheimer's Disease Symptoms & Early Diagnosis
Category: Slideshows
Created: 9/21/2015 12:00:00 AM
Last Editorial Review: 7/27/2016 12:00:00 AM
Caring for Someone With Alzheimer's Disease
Source: MedicineNet memantine Specialty [2016.05.16]
Title: Caring for Someone With Alzheimer's Disease
Category: Slideshows
Created: 2/16/2010 2:51:00 PM
Last Editorial Review: 5/16/2016 12:00:00 AM
7 Alzheimer's Disease Stages and Symptoms
Source: MedicineNet Advance Medical Directives Specialty [2016.05.12]
Title: 7 Alzheimer's Disease Stages and Symptoms
Category: Diseases and Conditions
Created: 7/30/2014 12:00:00 AM
Last Editorial Review: 5/12/2016 12:00:00 AM
Published Studies Related to Aricept (Donepezil)
The effect of a combination of gabapentin and donepezil in an experimental pain
model in healthy volunteers: Results of a randomized controlled trial. [2014]
This double-blind, placebo-controlled, 3-period cross-over, 4-treatment option,
incomplete block study (ClinicalTrials.gov number NCT01485185), with an adaptive
design for sample size re-estimation, was designed to evaluate gabapentin plus
donepezil in an established experimental model of electrical hyperalgesia...
Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for
the treatment of Alzheimer's disease: a systematic review and meta-analysis. [2014]
rivastigmine, and memantine for the treatment of AD... CONCLUSIONS: Cholinesterase inhibitors and memantine are able to stabilize or
Evaluation of an 8-item Severe Impairment Battery (SIB-8) vs. the full SIB in
moderate to severe Alzheimer's disease patients participating in a donepezil
study. [2013]
explored the SIB-8 scale with respect to its validity and sensitivity... CONCLUSIONS: In this post hoc analysis, similar treatment effects were measured
Ventricular enlargement and its clinical correlates in the imaging cohort from
the ADCS MCI donepezil/vitamin E study. [2013]
We analyzed the baseline and 3-year T1-weighted magnetic resonance imaging data
of 110 amnestic mild cognitive impairment (MCI) participants with minimal
hippocampal atrophy at baseline from the Alzheimer's Disease Cooperative Study
group MCI Donepezil/Vitamin E trial... Executive
decline was associated with right frontal and left temporal horn enlargement.
Donepezil and memantine for moderate-to-severe Alzheimer's disease. [2012]
disease... CONCLUSIONS: In patients with moderate or severe Alzheimer's disease, continued
Clinical Trials Related to Aricept (Donepezil)
Aricept to Improve Functional Tasks in Vascular Dementia [Active, not recruiting]
Medications for memory improvement are available but they may not actually improve the
ability to do real world tasks. The purpose of this research study is to determine if a
medicine used to treat memory problems donepezil(Aricept) enhances the ability to remember
steps of functional tasks and the actual ability to perform tasks relevant to real-life
independence. Aricept is an FDA approved medication for the treatment of Alzheimer's
disease. Aricept is an investigational drug for the purposes of this study, and is not
approved for this purpose.
A Double-blind Study of E2020 (Donepezil Hydrochloride) in Patients With Dementia With Lewy Bodies (DLB) (Study E2020-J081-431) [Completed]
The purpose of this study is to evaluate the efficacy and safety of E2020 in patients with
Dementia with Lewy Bodies (DLB).
Pharmacokinetic Comparisons of Two Donepezil Formulations [Completed]
To compare the relative bioavailability and pharmacokinetic characteristics of a newly
developed donepezil formulation with a conventional formulation in healthy subjects with a
single dose, randomized, open-label, 2-sequence - 2period crossover study.
Bioequivalence Study for Donepezil Hydrochloride Tablets 10 mg Under Fed Condition [Completed]
This is an open label, balanced, randomized, two-treatment, two-period, two sequence, single
dose, crossover, oral bioequivalence study.
Computerized Cognition Testing in Participants With Mild Alzheimer's Disease (AD) Treated With Donepezil (MK-0000-318) [Recruiting]
This study aims to determine whether the Cogstate testing battery can detect improvements in
cognitive function in participants with mild AD. The primary hypothesis is that the standard
deviation associated with the change from baseline in average One Card Learning (OCL)
repeated measurements after 12 weeks of donepezil treatment is =<0. 1
Reports of Suspected Aricept (Donepezil) Side Effects
Syncope (31),
Electrocardiogram QT Prolonged (26),
Convulsion (25),
Drug Interaction (24),
Fall (22),
Altered State of Consciousness (21),
Bradycardia (20),
Dementia (19),
Vomiting (19),
Loss of Consciousness (18), more >>
|
PATIENT REVIEWS / RATINGS / COMMENTSBased on a total of 9 ratings/reviews, Aricept has an overall score of 4.67. The effectiveness score is 5.56 and the side effect score is 6.44. The scores are on ten point scale: 10 - best, 1 - worst. Below are selected reviews: the highest, the median and the lowest rated.
| | Aricept review by care giver of 69 year old male patient | | | Rating |
| Overall rating: | |   |
| Effectiveness: | | Considerably Effective |
| Side effects: | | No Side Effects | | |
Treatment Info |
| Condition / reason: | | Alzheimers |
| Dosage & duration: | | 5g for one month rising to 10g (dosage frequency: daily) for the period of 3 months total - and on-going |
| Other conditions: | | None |
| Other drugs taken: | | None | | |
Reported Results |
| Benefits: | | Only moderate improvements noted on the 5g dosage.
Improvements much more noticeable at 10g - or after 30 days of taking medication. Less confusion, more awareness in social surroundings, more outward and positive in attitude. |
| Side effects: | | So far no negative noted |
| Comments: | | Take one pill in the morning.
Also vitamin supplements (Multi-vitamin, brain-booster vitamin, and homo-cysteine level reducer) |
|
| | Aricept review by care giver of 80 year old female patient | | | Rating |
| Overall rating: | | |
| Effectiveness: | | Ineffective |
| Side effects: | | Mild Side Effects | | |
Treatment Info |
| Condition / reason: | | Alzheimer's disease |
| Dosage & duration: | | 10 mg taken once daily for the period of 6 months |
| Other conditions: | | hernia, teeth problems |
| Other drugs taken: | | Tamasapan | | |
Reported Results |
| Benefits: | | We could not identify any benefits at all. The behavior and memory problems remained unchanged or worsened over time. Anxiety continued to increase and the dementia progressed systematically. Disorientation continued to increase and the patient became more and more difficult to manage. It appeared that irritability increased and the patient became more agitated more easily. |
| Side effects: | | There was some indication that there was at least some increase nausa as well as some infrequent but increased bouts of diarrhea. There were a few episodes of vomiting, but it might be attributed to other factors for this one side effect. There was definitely increased insomnia as well as loss of appetite, but it can not be definitively stated that the drug alone contributed to these although it did occur after the drug was begun. |
| Comments: | | The patient was given a daily dose. After transfer to a care facility, the regimentation in taking the dose was firmly set in place. Staff medical personnel on site did not observe any benefits, and as a result, after about 6 months the prescription was terminated. During the time the drug was used, there was a patient review every other week to ascertain whether there seemed to be any improvement in the patient. Memory tests were administered and one-on-one interviews were executed by medical personnel. The results of the memory testing showed no net improvement nor was there any identifiable changes that might be considered positive. Ultimately her psychiatrist in consultation with the family decided that the drug did not seem to provide any net gain. |
|
| | Aricept review by care giver of 67 year old female patient | | | Rating |
| Overall rating: | | |
| Effectiveness: | | Ineffective |
| Side effects: | | Severe Side Effects | | |
Treatment Info |
| Condition / reason: | | short term memory loss |
| Dosage & duration: | | 5 mg taken once for the period of once |
| Other conditions: | | severe head pain, feel like throwing up |
| Other drugs taken: | | welbutrin | | |
Reported Results |
| Benefits: | | none, only took one pill and found that the side effects do not warrant continued use. |
| Side effects: | | severe head pain, feel like throwing up, felt lousy for 12 hours after taking first pill. |
| Comments: | | Will not take pill again. The side effects of loosing a nights sleep, having severe head pain, and feeling like throwing up will result in not taking another pill as this drug does not agree with patient. |
|
|
|
Page last updated: 2017-06-01
|
